Array BioPharma begins phase 1 trial for cancer drug ARRY-334543

By Angela McDaniels

Seattle, Jan. 17 - Array BioPharma Inc. said it has begun dosing cancer patients in a phase 1 clinical trial for its targeted, small molecule, anti-cancer drug ARRY-334543.

"Advancing ARRY-334543 into clinical trials is a significant achievement for Array and further demonstrates our ability to invent novel therapies for cancer patients," president and chief scientific officer Kevin Koch said in a company news release.

"ARRY-334543 is our second targeted cancer agent resulting from our internal drug discovery program and furthers our goal of building the industry's leading clinical pipeline of small molecule drugs."

The open-label, dose-escalation trial is designed to evaluate tolerability and pharmacokinetics of ARRY-334543 following oral administration to patients with advanced cancer, Array said. The trial is also designed to examine indicators of therapeutic activity.

ARRY-334543 has shown significant anti-tumor activity in preclinical models of human breast, lung and epidermal carcinoma tumors, the company said.

ARRY-334543 is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 (Her-2/neu) and EGFR. Array said that over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients.

Currently, there is no single drug on the market that selectively inhibits both ErbB-2 and EGFR.

Array is a biopharmaceutical company based in Boulder, Colo., that discovers, develops and commercializes orally active drugs to address unmet medical needs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.